Umbilical Cord Blood Infusion for Elderly AML Patients
Author Information
Author(s): Wang Jinzeng, Li Xiaoyang, Liu Ping, Dai Yao, Zhu Hongming, Zhang Yunxiang, Wu Min, Yao Yunying, Liu Mingzhu, Yu Shuting, Jiang Fangying, Wang Shuai, Mu Haoran, Jiao Bo, Yan Hua, Wu Wen, Shen Yang, Li Junming, Wang Shengyue, Ren Ruibao
Primary Institution: Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Hypothesis
Is umbilical cord blood infusion an effective adjuvant therapy for elderly patients with acute myeloid leukemia?
Conclusion
Umbilical cord blood infusion is a safe and effective post-remission therapy for elderly patients with acute myeloid leukemia.
Supporting Evidence
- 51 patients were enrolled in the trial.
- The median overall survival was not yet reached.
- The median event-free survival was 72.2 months.
- 76.9% of patients were alive at 2 years.
- 62.8% of patients remained free of events at 2 years.
- No acute graft-versus-host disease occurred in any patient.
- The median time to platelet recovery was 11.5 days.
- The median time to neutrophil recovery was 12.2 days.
Takeaway
Doctors tested a new treatment using umbilical cord blood for older people with a type of blood cancer, and it helped many of them stay healthy longer.
Methodology
This was a prospective, single-arm, phase 2 trial where elderly AML patients received two cycles of chemotherapy combined with umbilical cord blood infusion.
Limitations
The study had a limited number of patients and a relatively short follow-up period.
Participant Demographics
The median age of participants was 66 years, with 58.8% female and 41.2% male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website